Phio Pharmaceuticals Corp.
PHIO
$1.99
-$0.10-4.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 24.02% | 236.36% | -2.18% | -64.38% | 1,667.35% |
| Gross Profit | -24.02% | -236.36% | 2.18% | 64.38% | -1,667.35% |
| SG&A Expenses | 17.84% | -7.07% | -10.05% | -2.27% | -9.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.64% | -15.26% | -5.58% | -42.72% | -24.85% |
| Operating Income | -20.64% | 15.26% | 5.58% | 42.72% | 24.85% |
| Income Before Tax | -17.33% | 17.87% | 14.20% | 45.18% | 27.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.33% | 17.87% | 14.20% | 45.18% | 27.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.33% | 17.87% | 14.20% | 45.18% | 27.58% |
| EBIT | -20.64% | 15.26% | 5.58% | 42.72% | 24.85% |
| EBITDA | -20.67% | 15.24% | 5.05% | 42.41% | 24.45% |
| EPS Basic | 87.52% | 12.67% | 74.77% | 84.99% | 72.74% |
| Normalized Basic EPS | 87.52% | 12.66% | 72.98% | 84.99% | 72.74% |
| EPS Diluted | 87.52% | 12.67% | 74.77% | 84.99% | 72.74% |
| Normalized Diluted EPS | 87.52% | 12.66% | 72.98% | 84.99% | 72.74% |
| Average Basic Shares Outstanding | 839.81% | -5.96% | 240.07% | 265.18% | 165.59% |
| Average Diluted Shares Outstanding | 839.81% | -5.96% | 240.07% | 265.18% | 165.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |